Summary
Vindesine (des-acetyl Vinblastine) is a synthetic derivative of vinblastine, and was produced with the hope that it would have less neurotoxicity and hematopoietic toxicity than other vinca alkaloids.
Phase I and II studies also demonstrated significant activity in lymphoid malignancies, especially Acute Lymphoblastic Leukemia (ALL). The present study was designed to compare therapeutic effectiveness of twice weekly vindesine (2 mg/M2/dose) plus Prednisone (60 mg/M2/dose) (Treatment 1) to weekly Vincristine (2 mg/M2/dose) plus Prednisone (60 mg/M2/day) (Treatment 2). All patients were less than 21 years of age, and had documented bone marrow relapse (blast count>25%). In 39 patients presumed sensitive to vincristine, there were 11 complete responses out of 20 patients (55%) randomized to receive vindesine/ prednisone and 7 complete responses out of 19 patients (37%) treated with Vincristine/Prednisone. In 37 patients resistant to vincristine, there were 7 complete responses (19%). Vindesine was more toxic than Vincristine. Major toxicities of vindesine included paraesthesias, peripheral neuropathy and ileus. Vindesine hematological toxicity appeared greater, but such toxicity is hard to assess in patients with bone marrow disease. In this study, vindesine and vincristine had similar efficacy, but vindesine use was associated with more toxicity.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Nelson RL, Root MA, Dyke RWet al.: Pharmacokinetics of desacetyl vinblastine amide (vindesine) in man (Abstract). Proc AACR ASCO 17:30, 1976
Sweeney MJ, Poore GA, Cullinan GJ,et al.: Experimental anti-tumor activity of desacetyl vinblastine amide (Abstract). Proc AACR ASCO 15:37, 1974
Komp D, Vats T, Shepherd D,et al.: Phase I evaluation of vindesine in children-pilot study. A Southwest Oncology Group study. Med Pediatr Oncol 243–250, 1980
Mathe G, Misset JC, De Vassal F,et al.: Phase II clinical trial with vindesine for remission induction in acute leukemia, blastic crisis of chronic myeloid leukemia, lymphosarcoma, and Hodgkin's disease: absence of crossresistance with vincristine. Cancer Treat Rep 62:805–809, 1978
Herson J, Starling KA, Dyment PG,et al.: Vincristine and prednisone vs. vincristine, L-asparaginase and prednisone for second remission induction of acute lymphocytic leukemia in children. Med Pediatr Oncol 6:317–323, 1979
Vats TS, Mehta P, Trueworthy RC,et al.: Vindesine and prednisone for remission induction in children with acute lymphocytic leukemia. Cancer 47:2789–2792, 1981
Anderson J, Krivit W, Chilcote R,et al.: Comparison of the therapeutic response of patients with childhood acute lym- phoblastic leukemia in relapse to vindesine versus vincristine in combination with prednisone and L-asparaginase. A phase III trial. Cancer Treat Rep 65:1015–1019, 1981
Krivit W, Anderson J, Chilcote R,et al.: A study of the cross-resistance of vincristine and vindesine in reinduction therapy for acute lymphocytic leukemia in relapse. Amer Journal of Pediatr Hematology/Oncology 2(3):217–221, 1980
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vats, T., Buchanan, G., Mehta, P. et al. A study of toxicity and comparative therapeutic efficacy of vindesine-prednisone vs. vincristine-prednisone in children with acute lymphoblastic leukemia in relapse. Invest New Drugs 10, 231–234 (1992). https://doi.org/10.1007/BF00877252
Issue Date:
DOI: https://doi.org/10.1007/BF00877252